7.67
price down icon0.78%   -0.06
after-market Dopo l'orario di chiusura: 7.68 0.010 +0.13%
loading
Precedente Chiudi:
$7.73
Aprire:
$7.72
Volume 24 ore:
269.59K
Relative Volume:
1.62
Capitalizzazione di mercato:
$163.96M
Reddito:
$66.59M
Utile/perdita netta:
$-104.93M
Rapporto P/E:
-1.5495
EPS:
-4.95
Flusso di cassa netto:
$-96.48M
1 W Prestazione:
+16.39%
1M Prestazione:
+6.82%
6M Prestazione:
+48.07%
1 anno Prestazione:
-47.75%
Intervallo 1D:
Value
$7.49
$7.89
Intervallo di 1 settimana:
Value
$6.435
$8.11
Portata 52W:
Value
$4.09
$15.92

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Name
Nome
Enanta Pharmaceuticals Inc
Name
Telefono
617 607 0800
Name
Indirizzo
4 KINGSBURY AVENUE, WATERTOWN, MA
Name
Dipendente
131
Name
Cinguettio
@EnantaPharma
Name
Prossima data di guadagno
2025-02-10
Name
Ultimi documenti SEC
Name
ENTA's Discussions on Twitter

Confronta ENTA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ENTA
Enanta Pharmaceuticals Inc
7.67 140.87M 66.59M -104.93M -96.48M -4.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-08-09 Downgrade JP Morgan Neutral → Underweight
2023-08-08 Downgrade Jefferies Buy → Hold
2022-12-09 Iniziato H.C. Wainwright Buy
2022-07-06 Aggiornamento Evercore ISI In-line → Outperform
2022-06-01 Aggiornamento Evercore ISI Underperform → In-line
2021-10-07 Iniziato Jefferies Buy
2021-09-09 Iniziato SVB Leerink Mkt Perform
2021-01-29 Aggiornamento JP Morgan Underweight → Neutral
2020-11-24 Iniziato Evercore ISI Underperform
2020-08-28 Ripresa ROTH Capital Buy
2020-08-26 Iniziato Piper Sandler Overweight
2020-07-27 Aggiornamento JMP Securities Mkt Perform → Mkt Outperform
2020-03-17 Aggiornamento Robert W. Baird Neutral → Outperform
2019-11-22 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2019-09-26 Downgrade JP Morgan Neutral → Underweight
2019-05-24 Iniziato Wolfe Research Outperform
2019-04-23 Aggiornamento Berenberg Hold → Buy
2018-12-13 Iniziato Berenberg Hold
2018-06-06 Iniziato ROTH Capital Buy
2018-02-08 Downgrade JP Morgan Overweight → Neutral
2018-01-02 Downgrade RBC Capital Mkts Outperform → Sector Perform
2017-11-21 Reiterato RBC Capital Mkts Outperform
2017-09-15 Iniziato RBC Capital Mkts Outperform
2017-07-11 Aggiornamento JMP Securities Mkt Perform → Mkt Outperform
2016-04-28 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 Reiterato Barclays Underweight
2015-10-23 Downgrade Barclays Equal Weight → Underweight
2015-10-23 Aggiornamento JMP Securities Mkt Perform → Mkt Outperform
Mostra tutto

Enanta Pharmaceuticals Inc Borsa (ENTA) Ultime notizie

pulisher
06:47 AM

Enanta Pharmaceuticals Inc. Stock Analysis and ForecastConsistent wealth multiplication - jammulinksnews.com

06:47 AM
pulisher
06:05 AM

Is Enanta Pharmaceuticals Inc. a good long term investmentHigh-yield capital appreciation - jammulinksnews.com

06:05 AM
pulisher
03:23 AM

Enanta Pharmaceuticals at Baird’s Biotech: Strategic Virology and Immunology Shift - Investing.com Canada

03:23 AM
pulisher
Jul 20, 2025

What analysts say about Enanta Pharmaceuticals Inc. stockStrong return on investment - printweek.in

Jul 20, 2025
pulisher
Jul 20, 2025

What drives Enanta Pharmaceuticals Inc. stock priceFree Investment Case Studies - Autocar Professional

Jul 20, 2025
pulisher
Jul 18, 2025

why enanta pharmaceuticals inc. stock attracts strong analyst attentionShort Term Risk Controlled Alerts - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Will Enanta Pharmaceuticals Inc. stock benefit from interest rate changesFast Growing Stocks - Newser

Jul 18, 2025
pulisher
Jul 16, 2025

Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series - BioSpace

Jul 16, 2025
pulisher
Jul 16, 2025

how enanta pharmaceuticals inc. stock performs during market volatilityFree Smart Investment Opportunities - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

What makes Enanta Pharmaceuticals Inc. stock price move sharplyBreakout Momentum Stocks - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

How Enanta Pharmaceuticals Inc. stock performs during market volatilityFree Investment Community - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Enanta Pharmaceuticals Inc. stock attracts strong analyst attentionVolume Spike Monitors - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

(ENTA) On The My Stocks Page - news.stocktradersdaily.com

Jul 12, 2025
pulisher
Jul 10, 2025

Enanta Pharmaceuticals Insider Buyers Net US$65k Despite 11% Stock Decline - simplywall.st

Jul 10, 2025
pulisher
Jun 21, 2025

(ENTA) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jun 21, 2025
pulisher
Jun 14, 2025

Enanta Pharmaceuticals’ SWOT analysis: stock shifts focus to immunology amid RSV progress - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 13, 2025

AbbVie Secures FDA Approval to Expand Mavyret’s Label - Yahoo Finance

Jun 13, 2025
pulisher
Jun 12, 2025

ENTA’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com

Jun 12, 2025
pulisher
Jun 11, 2025

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga

Jun 11, 2025
pulisher
Jun 11, 2025

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga

Jun 11, 2025
pulisher
Jun 11, 2025

AbbVie wins FDA nod for Mavyret label expansion (ABBV:NYSE) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approva - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus - Yahoo Finance

Jun 11, 2025
pulisher
Jun 10, 2025

(ENTA) Proactive Strategies - news.stocktradersdaily.com

Jun 10, 2025
pulisher
Jun 04, 2025

Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $24.00 Price Target at JMP Securities - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Enanta Pharma (ENTA) Receives Target Price Boost from JMP Securi - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Enanta (ENTA) Price Target Raised as Key Clinical Results Antici - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Enanta (ENTA) Price Target Raised as Key Clinical Results Anticipated | ENTA Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Citizens JMP raises Enanta Pharmaceuticals stock price target to $24 By Investing.com - Investing.com UK

Jun 03, 2025
pulisher
May 27, 2025

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - BioSpace

May 27, 2025
pulisher
May 27, 2025

Enanta Pharmaceuticals to Present at the Jefferies Global Health - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | ENTA Stock News - GuruFocus

May 27, 2025

Enanta Pharmaceuticals Inc Azioni (ENTA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Capitalizzazione:     |  Volume (24 ore):